Navigation Links
Potential new approach to treat cognitive impairments in schizophrenia

Philadelphia, PA, September 24, 2007 -- A new study reports important evidence for a potential new treatment approach for those diagnosed with schizophrenia. Schizophrenia is considered one of the most devastating of the major psychiatric disorders, which has three distinct facets, often referred to as positive (hallucinations, delusions), negative (blunted emotions, reduced capacity for pleasure), and cognitive (impairments in attention, memory, and problem-solving) symptoms. The cognitive impairments associated with schizophrenia are the aspect of this disorder most strongly associated with the inability to function in the workplace.

The medications currently approved to treat schizophrenia block a subclass of dopamine receptors (dopamine D2 receptors). They have limited efficacy in treating the negative and cognitive symptoms of this disorder and they are frequently associated with significant side effects. Hence, there is an acute need to develop alternative treatments for schizophrenia that have fewer side effects and are more effective in treating cognitive and negative symptoms of the disorder, according to the authors of this study, scheduled for publication in Biological Psychiatry on October 1st.

Multidisciplinary work has led to the emergence of the glutamate system as a promising therapeutic target for [the] treatment of schizophrenia, says Bita Moghaddam, Ph.D., the corresponding author on the study. Abnormal function of brain circuits that utilize glutamate as a chemical messenger, particularly in brain regions including the prefrontal cortex and hippocampus, has been implicated in the cognitive deficits associated with schizophrenia. The glutamate-related circuit dysfunction associated with schizophrenia may be modeled, to a meaningful extent, by blocking the NMDA subtype of glutamate receptor. The authors now report that by administering 3-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide or CDPPB, a drug that stimulates another type of glutamate receptor, the metabotropic glutamate 5 receptor (mGluR5), they can normalize abnormalities in prefrontal cortical function produced by blocking the NMDA glutamate receptor. In other words, CDPPB appears to treat an abnormality in brain function that may resemble aspects of schizophrenia.

Dr. Moghaddam comments, This work is significant because it shows that in an awake behaving mammal (as opposed to in tissue cultures or similar preparation), activation of these receptors has a normalizing effect on the spontaneous activity of prefrontal cortex neurons. John H. Krystal, M.D., Editor of Biological Psychiatry and affiliated with both Yale University School of Medicine and the VA Connecticut Healthcare System, adds, These exciting new data provide important new evidence supporting the testing of mGluR5 stimulating medications for the treatment of schizophrenia, particularly cognitive deficits associated with impairments in the function of the prefrontal cortex. It would be very interesting to know whether this class of medication reduces the transient impairments in cognitive function associated with the administration of NMDA receptor blockers to humans. Although the authors acknowledge that much more research is needed to evaluate the clinical impact of this treatment approach, this study indicates a promising therapeutic potential that could ultimately result in making improved treatments available to patients struggling with this illness.


Contact: Jayne Dawkins

Related medicine news :

1. Potential New Cancer Gene Identified
2. Lack of Smell And Its Potential Risks
3. New Blood Thinner Pill - First Potential Alternative to Warfarin in 50 years
4. The Potential Of Cadaver Transplantation Programme In India
5. Unwed mothers find it difficult to attract potential life partner
6. Another Potential Of Stem Cells Discovered: Used For Growing Cartilage
7. Unpasteurised juices found to be potential health hazards
8. The many facets of milk and its health potential
9. Artificial sweetener, Aspartame, may be the potential cause of lymphoma, leukaemia
10. Yoga Guru Ramdev Invited to Tap Ayurveda Potential by Jharkhand Govt
11. Alcohol a potential carcinogen: knocking on the door: pay heed!
Post Your Comments:
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and ... plans to open a flagship location in Covington, LA at 401 N. U.S. Highway ... store next to Office Depot in the Holiday Square shopping center. Its location allows ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( ... today the introduction of an innovative new design of the shoulder pad. The ... get maximum comfort while controlling your pain while using cold therapy. By utilizing ice ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... in post-acute health care, have expanded their existing home health joint venture through ... AccentCare has been operating a joint venture home health company with Asante, delivering ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... Mohebi Hair Restoration, has recently contributed a medical article to the newly revamped ... Dr. Mohebi’s article spotlights the hair transplant procedure known as Follicular ...
(Date:10/12/2017)... ... 12, 2017 , ... Leading pediatric oncology experts at Children’s National Health ... Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired ... Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... , Oct. 12, 2017 West ... in innovative solutions for injectable drug administration, today announced ... the market opens on Thursday, October 26, 2017, and ... results and business expectations at 9:00 a.m. Eastern Time. ... or 253-336-8738 (International). The conference ID is 94093362. ...
(Date:10/11/2017)... -- Caris Life Sciences ® , a leading innovator in ... medicine, today announced that St. Jude Medical Center,s Crosson ... as its 17 th member. Through participation with ... Institute will help develop standards of care and best ... cancer treatment more precise and effective. ...
(Date:10/11/2017)... 2017  Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today ... Las Piedras, Puerto Rico , where ... Following a comprehensive ... minor structural damage, temporary loss of power and minimal ... completed, manufacturing operations have resumed, and the company expects ...
Breaking Medicine Technology: